00:00Early results from Moderna's personalised mRNA cancer vaccine are a big deal,
00:06according to a US cancer specialist.
00:09Dr Ryan Sullivan says interim results from the therapy, developed with Merck
00:13and used alongside Keytruda, could reduce the risk of melanoma returning.
00:19This approach could potentially open the door to more personalised treatments for other types of cancer.
00:25The treatment combines Keytruda with a made-to-order mRNA vaccine
00:31designed using mutations identified in a patient's own tumour.
00:35The trial involved 1,137 high-risk patients with stage 2 B24 melanoma that had been surgically removed.
00:44Patients received up to nine doses of Keytruda and the personalised vaccine,
00:49or Keytruda alone, for around one year.
00:52The company said no new safety signals have emerged from the trial.
00:58Sullivan said he wants to see more details on the hazard ratio,
01:02including how much the treatment reduced the risk of recurrence and metastasis.
01:06He believes the therapy could be approved by the US Food and Drug Administration
01:11for wider use within the next two years.
01:14But he warned that producing personalised vaccines could create manufacturing and distribution challenges,
01:19with each treatment taking around four to six weeks to produce.
01:25In some ways, our enthusiasm is warranted, but also should be tempered a little bit,
01:31because we really haven't seen what the data looks like.
01:33We don't have those hazard ratios for reliance-free survival and dis-metastasis-free survival.
01:37We don't really know what the comparative toxicity is.
01:40We just know what the one-liner says.
01:43We just know what the one-liner says.
Comments